TY - JOUR A1 - Plötz, P.-A. A1 - Polyutov, S. P. A1 - Ivanov, S. D. A1 - Fennel, F. A1 - Wolter, S. A1 - Niehaus, T. A1 - Xie, Z. A1 - Lochbrunner, S. A1 - Würthner, Frank A1 - Kühn, O. T1 - Biphasic aggregation of a perylene bisimide dye identified by exciton-vibrational spectra JF - Physical Chemistry Chemical Physics N2 - The quantum efficiency of light emission is a crucial parameter of supramolecular aggregates that can be tuned by the molecular design of the monomeric species. Here, we report on a strong variation of the fluorescence quantum yield due to different phases of aggregation for the case of a perylene bisimide dye. In particular, a change of the dominant aggregation character from H- to J-type within the first aggregation steps is found, explaining the observed dramatic change in quantum yield. This behaviour is rationalised by means of a systematic study of the intermolecular potential energy surfaces using the time-dependent density functional based tight-binding (TD-DFTB) method. This provides a correlation between structural changes and a coupling strength and supports the notion of H- type stacked dimers and J-type stack-slipped dimers. The exciton-vibrational level structure is modelled by means of an excitonic dimer model including two effective vibrational modes per monomer. Calculated absorption and fluorescence spectra are found to be in reasonable agreement with experimental ones, thus supporting the conclusion on the aggregation behaviour. KW - Potential-energy curves KW - Simulations KW - Molecular-dynamics KW - Systems KW - Fluorescence KW - Sracking KW - Pathway KW - Dimers KW - State Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187387 VL - 18 IS - 36 ER - TY - JOUR A1 - Goebel, Werner A1 - Kathariou, S. A1 - Kuhn, M. A1 - Sokolovic, Z. A1 - Kreft, Jürgen A1 - Köhler, S. A1 - Funke, D. A1 - Chakraborty, T. A1 - Leimeister-Wächter, M. T1 - Hemolysin from Listeria-biochemistry, genetics and function in pathogenesis N2 - No abstract available KW - Biologie Y1 - 1988 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60563 ER - TY - JOUR A1 - Kohl, S. A1 - Gruendler, T. O. J. A1 - Huys, D. A1 - Sildatke, E. A1 - Dembek, T. A. A1 - Hellmich, M. A1 - Vorderwulbecke, M. A1 - Timmermann, L. A1 - Ahmari, S. E. A1 - Klosterkoetter, J. A1 - Jessen, F. A1 - Sturm, V. A1 - Visser-Vandewalle, V. A1 - Kuhn, J. T1 - Effects of deep brain stimulation on prepulse inhibition in obsessive-compulsive disorder JF - Translational Psychiatry N2 - Owing to a high response rate, deep brain stimulation (DBS) of the ventral striatal area has been approved for treatment-refractory obsessive-compulsive disorder (tr-OCD). Many basic issues regarding DBS for tr-OCD are still not understood, in particular, the mechanisms of action and the origin of side effects. We measured prepulse inhibition (PPI) in treatment-refractory OCD patients undergoing DBS of the nucleus accumbens (NAcc) and matched controls. As PPI has been used in animal DBS studies, it is highly suitable for translational research. Eight patients receiving DBS, eight patients with pharmacological treatment and eight age-matched healthy controls participated in our study. PPI was measured twice in the DBS group: one session with the stimulator switched on and one session with the stimulator switched off. OCD patients in the pharmacologic group took part in a single session. Controls were tested twice, to ensure stability of data. Statistical analysis revealed significant differences between controls and (1) patients with pharmacological treatment and (2) OCD DBS patients when the stimulation was switched off. Switching the stimulator on led to an increase in PPI at a stimulus-onset asynchrony of 200 ms. There was no significant difference in PPI between OCD patients being stimulated and the control group. This study shows that NAcc-DBS leads to an increase in PPI in tr-OCD patients towards a level seen in healthy controls. Assuming that PPI impairments partially reflect the neurobiological substrates of OCD, our results show that DBS of the NAcc may improve sensorimotor gating via correction of dysfunctional neural substrates. Bearing in mind that PPI is based on a complex and multilayered network, our data confirm that DBS most likely takes effect via network modulation. KW - nucleus KW - serotonin KW - schizophrenia KW - dopamine KW - double-blind KW - psychiatric disorders KW - in vivo KW - acoustic startle KW - reflex KW - modulation Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-138300 VL - 5 IS - e675 ER - TY - JOUR A1 - Herbert, S. L. A1 - Wöckel, A. A1 - Kreienberg, R. A1 - Kühn, T. A1 - Flock, F. A1 - Felberbaum, R. A1 - Janni, W. A1 - Curtaz, C. A1 - Kiesel, M. A1 - Stüber, T. A1 - Diessner, J. A1 - Salmen, J. A1 - Schwentner, L. A1 - Fink, V. A1 - Bekes, I. A1 - Leinert, E. A1 - Lato, K. A1 - Polasik, A. A1 - Schochter, F. A1 - Singer, S. T1 - To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis? JF - Breast Cancer Research and Treatment N2 - Objective In this study, we investigated to which extent patients feel well informed about their disease and treatment, which areas they wish more or less information and which variables are associated with a need for information about the disease, medical tests and treatment. Methods In a German multi-centre prospective study, we enrolled 759 female breast cancer patients at the time of cancer diagnosis (baseline). Data on information were captured at 5 years after diagnosis with the European Organisation for Research and Treatment of Cancer (EORTC) Information Module (EORTC QLQ-INFO24). Good information predictors were analysed using linear regression models. Results There were 456 patients who participated at the 5-year follow-up. They reported to feel well informed about medical tests (mean score 78.5) and the disease itself (69.3) but relatively poorly about other services (44.3) and about different places of care (31.3). The survivors expressed a need for more information concerning: side effects and long-term consequences of therapy, more information in general, information about aftercare, prognosis, complementary medicine, disease and therapy. Patients with higher incomes were better informed about medical tests (β 0.26, p 0.04) and worse informed with increasing levels of fear of treatment (β − 0.11, p 0.02). Information about treatment was reported to be worse by survivors > 70 years old (β -0.34, p 0.03) and by immigrants (β -0.11, p 0.02). Survivors who had received additional written information felt better informed about disease, medical tests, treatment and other services (β 0.19/0.19/0.20/0.25; each p < 0.01). Conclusion Health care providers have to reconsider how and what kind of information they provide. Providing written information, in addition to oral information, may improve meeting those information needs. KW - breast cancer KW - survivors KW - unmet needs KW - health care providers Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232356 SN - 0167-6806 VL - 185 ER - TY - JOUR A1 - Schade, A. A1 - Bader, A. A1 - Huber, T. A1 - Kuhn, S. A1 - Czyszanowski, T. A1 - Pfenning, A. A1 - Rygała, M. A1 - Smołka, T. A1 - Motyka, M. A1 - Sęk, G. A1 - Hartmann, F. A1 - Höfling, S. T1 - Monolithic high contrast grating on GaSb/AlAsSb based epitaxial structures for mid-infrared wavelength applications JF - Optics Express N2 - We demonstrate monolithic high contrast gratings (MHCG) based on GaSb/AlAs0.08Sb0.92 epitaxial structures with sub-wavelength gratings enabling high reflection of unpolarized mid-infrared radiation at the wavelength range from 2.5 to 5 µm. We study the reflectivity wavelength dependence of MHCGs with ridge widths ranging from 220 to 984 nm and fixed 2.6 µm grating period and demonstrate that peak reflectivity of above 0.7 can be shifted from 3.0 to 4.3 µm for ridge widths from 220 to 984 nm, respectively. Maximum reflectivity of up to 0.9 at 4 µm can be achieved. The experiments are in good agreement with numerical simulations, confirming high process flexibility in terms of peak reflectivity and wavelength selection. MHCGs have hitherto been regarded as mirrors enabling high reflection of selected light polarization. With this work, we show that thoughtfully designed MHCG yields high reflectivity for both orthogonal polarizations simultaneously. Our experiment demonstrates that MHCGs are promising candidates to replace conventional mirrors like distributed Bragg reflectors to realize resonator based optical and optoelectronic devices such as resonant cavity enhanced light emitting diodes and resonant cavity enhanced photodetectors in the mid-infrared spectral region, for which epitaxial growth of distributed Bragg reflectors is challenging. KW - monolithic grating KW - high contrast KW - mid-infrared wavelength applications KW - epitaxial structures KW - GaSb/AlAsSb Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-350346 VL - 31 IS - 10 ER - TY - JOUR A1 - Thomas, Sarah A1 - Fiebig, Juliane E. A1 - Kuhn, Eva-Maria A1 - Mayer, Dominik S. A1 - Filbeck, Sebastian A1 - Schmitz, Werner A1 - Krischke, Markus A1 - Gropp, Roswitha A1 - Mueller, Thomas D. T1 - Design of glycoengineered IL-4 antagonists employing chemical and biosynthetic glycosylation JF - ACS Omega N2 - Interleukin-4 (IL-4) plays a key role in atopic diseases. It coordinates T-helper cell differentiation to subtype 2, thereby directing defense toward humoral immunity. Together with Interleukin-13, IL-4 further induces immunoglobulin class switch to IgE. Antibodies of this type activate mast cells and basophilic and eosinophilic granulocytes, which release pro-inflammatory mediators accounting for the typical symptoms of atopic diseases. IL-4 and IL-13 are thus major targets for pharmaceutical intervention strategies to treat atopic diseases. Besides neutralizing antibodies against IL-4, IL-13, or its receptors, IL-4 antagonists can present valuable alternatives. Pitrakinra, an Escherichia coli-derived IL-4 antagonist, has been evaluated in clinical trials for asthma treatment in the past; however, deficits such as short serum lifetime and potential immunogenicity among others stopped further development. To overcome such deficits, PEGylation of therapeutically important proteins has been used to increase the lifetime and proteolytic stability. As an alternative, glycoengineering is an emerging strategy used to improve pharmacokinetics of protein therapeutics. In this study, we have established different strategies to attach glycan moieties to defined positions in IL-4. Different chemical attachment strategies employing thiol chemistry were used to attach a glucose molecule at amino acid position 121, thereby converting IL-4 into a highly effective antagonist. To enhance the proteolytic stability of this IL-4 antagonist, additional glycan structures were introduced by glycoengineering utilizing eucaryotic expression. IL-4 antagonists with a combination of chemical and biosynthetic glycoengineering could be useful as therapeutic alternatives to IL-4 neutralizing antibodies already used to treat atopic diseases. KW - Interleukin-4 (IL-4) KW - atopic diseases KW - IL-4 antagonists KW - glycoengineering KW - biosynthetic glycosylation KW - chemical glycosylation Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-350278 SN - 2470-1343 VL - 8 IS - 28 ER -